Literature DB >> 4630981

Properdin anc C3 proactivator: alternate pathway components in human glomerulonephritis.

R H McLean, A F Michael.   

Abstract

Serological and immunopathological studies of human glomerulonephritis have suggested that alternate pathways of activation of the third component of complement may be important in some forms of glomerulonephritis. We have investigated the role of two alternate pathway proteins, properdin and C3 proactivator, in 22 patients with chronic membranoproliferative glomerulonephritis, 21 patients with systemic lupus erythematosus, 20 patients with acute poststreptococcal glomerulonephritis, and 19 patients with other forms of renal disease. C3 (measured at beta(1)A), properdin, and C3 proactivator were assayed by single radial immunodiffusion. In sera with low beta(1)A (< 2 SD), mean properdin was most significantly decreased in patients with acute poststreptococcal glomerulonephritis but was also significantly decreased in chronic membranoproliferative glomerulonephritis and in untreated systemic lupus erythematosus. Properdin levels in other renal disease, acute glomerulonephritis, and chronic membranoproliferative glomerulonephritis with normal beta(1)A levels were not significantly different from normal. A positive correlation between beta(1)A and properdin levels in individual sera was present in all diseases except systemic lupus erythematosus. Serum C3 proactivator was markedly decreased in active systemic lupus erythematosus and there was a positive correlation between beta(1)A and C3 proactivator levels in systemic lupus erythematosus and other renal diseases but not acute poststreptococcal glomerulonephritis. Properdin in fresh sera from four patients with systemic lupus erythematosus and five with chronic membranoproliferative glomerulonephritis showed increased migration toward the cathode on immunoelectrophoresis, suggesting in vivo change of the properdin molecule. The observation of reduced serum levels of properdin and C3 proactivator and altered electrophoretic migration of properdin in some patients with glomerulonephritis provide new evidence for participation of these alternate pathway proteins in glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4630981      PMCID: PMC302302          DOI: 10.1172/JCI107225

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Properties of highly purified human properdin.

Authors:  J Ensky; C F Hinz; E W Todd; R J Wedgwood; J T Boyer; I H Lepow
Journal:  J Immunol       Date:  1968-01       Impact factor: 5.422

2.  Complement utilization by guinea pig 1 and 2-immunoglobulins through the C3 activator system.

Authors:  A L Sandberg; O Götze; H J Müller-Eberhard; A G Osler
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

3.  The biologic activities of guinea pig antibodies. II. Modes of complement interaction with gamma 1 and gamma 2-immunoglobulins.

Authors:  A L Sandberg; A G Osler; H S Shin; B Oliveira
Journal:  J Immunol       Date:  1970-02       Impact factor: 5.422

4.  The biologic activities of guinea pig antibodies. I. Separation of gamma1 and gamma2 immunoglobulins and their participation in allergic reactions of the immediate type.

Authors:  B Oliveira; A G Osler; R P Siraganian; A L Sandberg
Journal:  J Immunol       Date:  1970-02       Impact factor: 5.422

5.  Epidemic acute glomerulonephritis associated with type 49 streptococcal pyoderma. II. Correlative study of light, immunofluorescent and electron microscopic findings.

Authors:  A J Fish; R C Herdman; A F Michael; R J Pickering; R A Good
Journal:  Am J Med       Date:  1970-01       Impact factor: 4.965

6.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

7.  Serial complement component alterations in acute glomerulonephritis and systemic lupus erythematosus.

Authors:  P F Kohler; R Ten Bensel
Journal:  Clin Exp Immunol       Date:  1969-02       Impact factor: 4.330

8.  Decreased properdin activity in acute glomerulonephritis.

Authors:  H Gewurz; R J Pickering; G Naff; R Snyderman; S E Mergenhagen; R A Good
Journal:  Int Arch Allergy Appl Immunol       Date:  1969

9.  Glomerular deposition of properdin in acute and chronic glomerulonephritis with hypocomplementemia.

Authors:  N G Westberg; G B Naff; J T Boyer; A F Michael
Journal:  J Clin Invest       Date:  1971-03       Impact factor: 14.808

10.  Characteristics of a non-complement-dependent C3-reactive complex formed form factors in nephritic and normal serum.

Authors:  E H Vallota; J Forristal; R E Spitzer; N C Davis; C D West
Journal:  J Exp Med       Date:  1970-06-01       Impact factor: 14.307

View more
  34 in total

1.  The effect of anticomplementary substances on properdin in normal and C2-deficient sera.

Authors:  R H McLean; K Townsend; A F Michael
Journal:  Clin Exp Immunol       Date:  1975-03       Impact factor: 4.330

2.  Classical and alternative complement pathway activation by pneumococci.

Authors:  C G Stephens; R C Williams; W P Reed
Journal:  Infect Immun       Date:  1977-08       Impact factor: 3.441

3.  Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.

Authors:  L H Perrin; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

4.  Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.

Authors:  J A Charlesworth; D G Williams; E Sherington; P J Lachmann; D K Peters
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

5.  Influence of a deficiency of the second component of complement on the bactericidal activity of neutrophils in vitro.

Authors:  J E Repine; C C Clawson; P S Friend
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

6.  Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus.

Authors:  D Adu; D G Williams
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

7.  The secretory immune system and renal disease.

Authors:  R S Dobrin; F E Knudson; A F Michael
Journal:  Clin Exp Immunol       Date:  1975-08       Impact factor: 4.330

8.  Mechanisms of activation of the properdin system. Studies on properdin electrophoretic mobility in agarose activation of the alternative pathway.

Authors:  C Adam; D G Williams; D K Peters
Journal:  Clin Exp Immunol       Date:  1975-11       Impact factor: 4.330

9.  C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.

Authors:  K Whaley; P H Schur; S Ruddy
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

10.  Dichotomy between opsonization and serum complement activation by encapsulated staphylococci.

Authors:  P K Peterson; Y Kim; B J Wilkinson; D Schmeling; A F Michael; P G Quie
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.